摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-cyclopropyl-1-(5-(6,7-dimethoxycinnolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-ol | 1119717-50-8

中文名称
——
中文别名
——
英文名称
4-cyclopropyl-1-(5-(6,7-dimethoxycinnolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-ol
英文别名
4-cyclopropyl-1-[5-(6,7-dimethoxycinnolin-4-yl)-3-methylpyridin-2-yl]piperidin-4-ol
4-cyclopropyl-1-(5-(6,7-dimethoxycinnolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-ol化学式
CAS
1119717-50-8
化学式
C24H28N4O3
mdl
——
分子量
420.511
InChiKey
KNRZYEZDOHOQNW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    618.8±65.0 °C(predicted)
  • 密度:
    1.284±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    80.6
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PHOSPHODIESTERASE 10 INHIBITORS
    申请人:Hu Essa
    公开号:US20090062277A1
    公开(公告)日:2009-03-05
    The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula where R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
    本发明涉及一些化合物,这些化合物可用作磷酸二酯酶10(PDE10)抑制剂,其具有以下结构式:其中R1、R2、R3、R4、X、Y和Z如本文所定义,包含这些化合物的药物组合物以及制备这些化合物的方法。该发明还涉及治疗由PDE10介导的疾病的方法,如肥胖、非胰岛素依赖性糖尿病、精神分裂症、躁郁症、强迫症等。
  • [EN] PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
    申请人:AMGEN INC
    公开号:WO2009025823A1
    公开(公告)日:2009-02-26
    The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula (I), where R1, R2, R3, R4, X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
  • Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors
    作者:Essa Hu、Roxanne K. Kunz、Shannon Rumfelt、Ning Chen、Roland Bürli、Chun Li、Kristin L. Andrews、Jiandong Zhang、Samer Chmait、Jeffrey Kogan、Michelle Lindstrom、Stephen A. Hitchcock、James Treanor
    DOI:10.1016/j.bmcl.2012.01.086
    日期:2012.3
    We report the discovery of 6,7-dimethoxy-4-(pyridin-3-yl)cinnolines as novel inhibitors of phosphodiesterase 10A (PDE10A). Systematic examination and analyses of structure–activity-relationships resulted in single digit nM potency against PDE10A. X-ray co-crystal structure revealed the mode of binding in the enzyme’s catalytic domain and the source of selectivity against other PDEs. High in vivo clearance
    我们报告发现6,7-二甲氧基-4-(吡啶-3-基)cinnolines作为磷酸二酯酶10A(PDE10A)的新型抑制剂。对结构-活性关系的系统检查和分析导致抗PDE10A的位数为nM。X射线共晶体结构揭示了酶催化结构域中的结合模式以及对其他PDE的选择性来源。借助代谢物鉴定(ID)研究解决了大鼠体内高清除率的问题。这些发现共同产生了化合物39,它是一种有前途的有效PDE10A抑制剂,在大鼠中具有良好的体内代谢稳定性,并在啮齿动物行为模型中具有功效。
查看更多